Last Updated 2 November 2015
Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year forecast period. This comes despite biosimilar erosion expected for rituximab, the patient share and sales leader in 2014, and generic erosion for bendamustine, the second best-selling agent across the NHL market in 2014. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.
Questions Answered in This Report:
- The first kinase inhibitors for NHL were approved in late 2013. How has the treatment algorithm of NHL changed as a result of their approval? Which other kinase inhibitors are most promising in NHL? Which patient populations are kinase inhibitors most likely to target? What will be their impact to the NHL market?
- Rituximab is widely used across all NHL drug-treated populations and garners significant sales; however, rituximab faces an enormous threat by the entry of biosimilars, as well as new drugs like obinutuzumab. How will market share for rituximab change over our ten-year forecast period as a result of biosimilar and new drug entries? How will Roche seek to minimize the impact of biosimilar erosion of branded rituximab?
- The NHL market will experience robust growth through 2024. What factors are driving this growth? Which drug class will dominate the treatment of NHL? What new classes of agents will emerge over the ten-year forecast period, and what will be their market impact?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 27 country-specific interviews with experts and 213 country-specific surveys with hematological oncologists treating NHL.
Epidemiology: Diagnosed incidence for FL, CLL/SLL, DLBCL, and MCL.
Population segments in market forecast: First line, second line, and third line, for FL, CLL/SLL, DLBCL, and MCL.
Emerging therapies: Phase II: 16 drugs; Phase III: 7 drugs; preregistration: 0 drugs; registered: 0 drugs. Coverage of 18 select Phase I products.